Please provide your email address to receive an email when new articles are posted on . The FDA recently issued approval to the first generic version of ...

Advair 250/50 Now the Only Treatment Approved to Both Reduce Exacerbations and Improve Lung Function RESEARCH TRIANGLE PARK, N.C., May 1 -- Late yesterday the U.S. Food and Drug Administration ...

PHILADELPHIA, June 1, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for ...

Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...

The Food and Drug Administration has accepted Lannett’s abbreviated new drug application for fluticasone propionate and salmeterol inhalation powder in three strengths — a generic of GlaxoSmithKline's ...

LONDON, April 20, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline's ...

LONDON, Dec. 17, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of ...

A number of well-known GlaxoSmithKline drugs, including one major blockbuster, will no longer be covered by the largest pharmacy benefit manager in the U.S. beginning Jan. 1. The pharmacy benefit ...

Advair Diskus 250/50 is the only approved strength for COPD because an efficacy advantage of the higher strength Advair Diskus 500/50 over Advair Diskus 250/50 has not been demonstrated. Patients ...

PHILADELPHIA, June 1, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for ...